Business Insider23d
Positive Outlook for Disc Medicine’s Bitopertin: Buy Rating Supported by Strategic APOLLO Trial Developments and FDA Alignment
primarily focusing on the positive outlook for Disc Medicine’s Bitopertin in treating EPP/XLP. The recent FDA Type C meeting resulted in an alignment on dual primary endpoints for the APOLLO ...
Yahoo Finance24d
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission
Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ ... today announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the APOLLO ...